Dupilumab tab 300mg 2ml patent expiry information for us?

Quick clarifications and then how to get exact details:

- Dupilumab is not a tablet. It’s a biologic injectable (Dupixent). Packaging can be 300 mg in 2 mL per vial/pre-filled syringe, but there are no “Dupilumab tablets.”

- Patent expiry for Dupilumab in the US is not a single date. There are multiple patent families (composition of matter, anti-IL-4 receptor alpha antibody, methods of use, etc.) owned by Regeneron and Sanofi. Each patent family has its own expiration date, and some may include term adjustments. In addition, US data exclusivity for a new biologic is typically 12 years from the first FDA approval, which for dupilumab was 2017 (so around 2029 for data exclusivity), with potential pediatric exclusivity adding more time in some cases. This is separate from patent expiration and can affect timing of biosimilar competition.

What I can do next (if you want exact dates):
- Look up the US patent families for dupilumab (Regeneron/Sanofi) on USPTO Patent Center and Google Patents, and list:
- Patent family numbers
- Issuance/grant dates and expiration dates (including any term adjustments)
- Whether they cover composition of matter, function, or methods of use
- Note any regulatory data exclusivity expiration dates as of the latest filings.

If you’d like me to pull the current US patent expiry details and summarize them with exact patent numbers and dates, say “Yes, please fetch the latest patent data,” and I’ll guide you through the findings or provide a concise list.